Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Inclusion Criteria:

1. Biopsy of breast mass was performed under ultrasound-guided treatment beforeneoadjuvant chemotherapy, and the diagnosis of breast cancer was confirmedpathologically, followed by immunohistochemical examination. Pathological sectionsbefore and after neoadjuvant chemotherapy were jointly diagnosed by 3 or more seniorpathologists, and there were consistent definite conclusions.
2. Have detailed and complete clinicopathological data;
3. Diagnosis data of TCM syndrome type;
4. No biopsy-confirmed lymph node metastasis;
5. No serious systemic disease, able to tolerate neoadjuvant chemotherapy and surgicaltreatment;
6. At least 4 cycles of neoadjuvant chemotherapy were completed, and the efficacy ofchemotherapy was evaluated at the end of chemotherapy and after surgery;
7. Under the guidance of doctors, take Xihuang pills in a standardized way throughout thewhole process and review regularly;
8. The patient did not receive any antitumor therapy drugs associated with the tumorprior to neoadjuvant chemotherapy;
9. All patients were newly diagnosed

Exclusion Criteria:

1. Concurrent malignant tumors of other sites;
2. Patients with distant metastasis
3. Male breast cancer
4. Patients who did not receive full-course standardized neoadjuvant chemotherapy;
5. Lost contact or dropped out of the study, unable to follow up;
6. Inability to tolerate chemotherapy responses;
7. Intolerant to Xihuang Wan and unable to take it;
8. The patient has strong side effects of chemotherapy and cannot tolerate chemotherapydrugs;
9. Inflammatory breast cancer, bilateral breast cancer, paget's disease and other specialtypes of breast cancer;
10. Various other possible influences.